Rodan + Fields Review- Scam

  • 11

An action brought against Rodan + Fields because of a secret component in their Lash Boost product has been settled. Isopropyl cloprostenate, a medicine for glaucoma, is at the center of the controversy. A class action lawsuit was launched against Rodan + Fields in 2018 by Barbara Lewis, Akemi Buckingham, Elaina Hufnagel, and Tereas Gattuso. According to the four plaintiffs, Rodan + Fields has failed to disclose important information to Lash Boost customers concerning a component called isopropyl cloprostenate since it was introduced to the market in 2016.   

Synthetic prostaglandin analog, isopropyl cloprostenate. Patients with ocular hypertension who have elevated ocular pressure can benefit from the use of prostaglandin analogs in their glaucoma treatment.  In spite of the fact that prostaglandin analogs have “potentially sight-threatening side effects,” including:

a. iris cysts and cystoid macular effusion (which may cause vision loss or distortion);

b. inflammation of the iris or ciliary body;

c. reactivation of herpes simplex keratitid; and,

d. corneal necrosis (which may cause scarring) (inflammation and possible scarring of the cornea).   

As well as periorbital fat atrophy, which causes the eyelid to droop and can lead to periorbital fat necrosis, there are also known side effects, such as darkening of the eyelid skin, increased prominence of the lid vessels, darkening of the skin beneath the eyes, and lengthening of the eyelashes.   

The inclusion of isopropyl cloprostenate in Lash Boost is likely related to “lengthening of eyelashes,” given that it is an “eyelash booster.”   

The plaintiffs claim that the FDA notified another cosmetic producer in 2011 about the use of isopropyl cloprostenate and that another manufacturer did inform consumers of the potential negative effects of this ingredient.   

Since Rodan + Fields doesn’t have to go through the FDA approval procedure and disclose the risks of prostaglandin analogs, they can sell Lash Boost as a cosmetic.   

They went on to allege that people who used Lash Boost had eyelid droop, itchy eyes, and eyelid discoloration. They also claimed that people who used the product had thinning of hair around their eyes as well as vision problems.   

Rodan + Fields engaged in deceptive, unfair, and illegal marketing tactics by not communicating the risks and side effects of Lash Boost and allowing customers to decide for themselves if the risk was worth it.   

A class action lawsuit has been filed on behalf of consumers who purchased Rodan + Field’s Lash Boost at a $150 per tube cost, claiming the company was “the top selling skincare brand in 2016” and generated over “$1 billion in sales”.   

However, plaintiffs claim that their class action does not allege that Lash Boost is or should have been subject to FDA regulation, which is odd. I’d have assumed that Rodan & Fields’ inability to disclose potentially harmful side effects of their products was under the FDA’s purview. Perhaps the FTC could take a look at it.

To put it another way, considering the nature of the allegations, this is an unusual remark to make. It was only now that I became aware of a class-action lawsuit against Rodan + Fields that was filed in April 2018.

On the basis of the docket, it appears that the case went on for another four years. Early on, it was consolidated with two other similar class actions. At some point, some of the plaintiffs were dismissed because they had achieved individual settlements with Rodan + Fields.

There was a “Proposed Order Regarding Settlement” filed in June of 2021. On September 28th, 2021, the parties signed a settlement agreement. Plaintiffs in a class-action lawsuit submitted a request to dismiss the case on April 7, 2022, concluding the settlement that had been negotiated.

Asserting their innocence, Rodan + Fields agreed to update the [Lash Boost] label and directions for use and to disclose certain purported negative effects that have been experienced by some product users.   

This product’s advertising and training materials will be revised by R+F, including the addition of more explicit warnings about potential risks and other important information about how to use R+F Independent Consultants.   

The agreement’s monetary value could reach $38 million.   

Settlement payments totaling $30 million have been made in cash as a result of this settlement. Eight million dollars are left over as a credit for Rodan + Fields products. In order to become a Certified Class Member, you must have purchased Lash Boost between October 1, 2016, and March 11, 2022. Rodan + Fields product credit vouchers and cash payments are available to class participants via the claim form.

According to a court-ordered settlement letter, the maximum credit benefit is $250 and the maximum cash reward is $175.   

A “Credit Repeat Purchaser Benefit” of up to $250 or a “Cash Repeat Purchaser Benefit” of up to $175 is available to Settlement Class Members who produce evidence of purchase confirming that they have purchased Lash Boost more than once, for a total benefit of $500 in credit or $350 in cash. 

There is a $500 credit or $350 cash reward for purchasing more than one bottle of Lash Boostup, depending on how many bottles you have purchased. 

There is a $38 million settlement fund, but not all of it is going to class members. An estimated $425,608 is removed from the $30 million component for settlement administrative costs.   

Fees for legal representation (limited to $15.4 million)   

There are 11 class representative service awards of $15,000 apiece, which totals $165,000 for the 11 representatives. 

Cash claims will be reduced if there isn’t enough left to cover them. 

Membership in the class is optional. The deadline for students to withdraw from the class is July 14th. Claim Forms for members of the class must be submitted by the 7th of September 2022.

Class members have access to a website that allows them to file claims (the blue “start your claim” button on the right of the page).

Any questions that members of the impacted class may have should be addressed in the Settlement Notice that was provided.

Contact information for the Settlement Administrator and/or Class Counsel is also supplied in the event that this is not possible.

For the avoidance of doubt, we are not a law firm that can offer you individual legal advice.

An action brought against Rodan + Fields because of a secret component in their Lash Boost product has been settled. Isopropyl cloprostenate, a medicine for glaucoma, is at the center of the controversy. A class action lawsuit was launched against Rodan + Fields in 2018 by Barbara Lewis, Akemi Buckingham, Elaina Hufnagel, and Tereas Gattuso.…

An action brought against Rodan + Fields because of a secret component in their Lash Boost product has been settled. Isopropyl cloprostenate, a medicine for glaucoma, is at the center of the controversy. A class action lawsuit was launched against Rodan + Fields in 2018 by Barbara Lewis, Akemi Buckingham, Elaina Hufnagel, and Tereas Gattuso.…

Leave a Reply

Your email address will not be published.